-+ 0.00%
-+ 0.00%
-+ 0.00%

Connect Biopharma Seabreeze STAT Phase 2 trials continue unchanged after interim review

PUBT·04/23/2026 13:04:57
Listen to the news
Connect Biopharma Seabreeze STAT Phase 2 trials continue unchanged after interim review
  • Connect Biopharma kept Phase 2 Seabreeze STAT asthma and COPD trials for rademikibart on track following a pre-specified interim efficacy review by an independent Data Monitoring Committee.
  • Committee recommended no change to planned sample size, supporting continued enrollment as designed.
  • Safety review flagged no concerns, with no treatment-related serious or severe adverse events reported to date.
  • Topline results have not been presented yet; Connect expects to report topline data from both studies in mid-2026.
  • Positive readouts would position Connect to seek FDA alignment on a Phase 3 program for acute exacerbations of asthma and COPD.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604230900PRIMZONEFULLFEED9695556) on April 23, 2026, and is solely responsible for the information contained therein.